Sonnet BioTherapeutics Files 8-K
| Field | Detail |
|---|---|
| Company | Sonnet Biotherapeutics Holdings, Inc. |
| Form Type | 8-K |
| Filed Date | Jul 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, other-events
TL;DR
Sonnet BioTherapeutics filed an 8-K, something happened on 7/23.
AI Summary
Sonnet BioTherapeutics Holdings, Inc. filed an 8-K on July 25, 2025, reporting an event on July 23, 2025. The filing is categorized under 'Other Events' and does not provide specific details about the nature of the event or any associated financial figures.
Why It Matters
This 8-K filing indicates a material event has occurred for Sonnet BioTherapeutics, requiring disclosure to investors, though the specific details are not yet public.
Risk Assessment
Risk Level: medium — The filing of an 8-K under 'Other Events' suggests a significant development, but the lack of detail creates uncertainty for investors.
Key Players & Entities
- Sonnet BioTherapeutics Holdings, Inc. (company) — Registrant
- July 23, 2025 (date) — Earliest event date
- July 25, 2025 (date) — Filing date
- 100 Overlook Center, Suite 102 Princeton, New Jersey 08540 (location) — Principal executive offices
FAQ
What specific event prompted Sonnet BioTherapeutics Holdings, Inc. to file this 8-K?
The filing does not specify the exact event, only that it occurred on July 23, 2025, and is categorized under 'Other Events'.
When was this 8-K filing submitted to the SEC?
The 8-K was filed on July 25, 2025.
What is the principal executive office address for Sonnet BioTherapeutics Holdings, Inc.?
The principal executive offices are located at 100 Overlook Center, Suite 102, Princeton, New Jersey 08540.
What is the Commission File Number for Sonnet BioTherapeutics Holdings, Inc.?
The Commission File Number is 001-35570.
What is the IRS Employer Identification Number (EIN) for the company?
The IRS Employer Identification Number is 20-2932652.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 25, 2025 regarding Sonnet BioTherapeutics Holdings, Inc..